AR018321A1 - Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. - Google Patents

Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.

Info

Publication number
AR018321A1
AR018321A1 ARP990100963A ARP990100963A AR018321A1 AR 018321 A1 AR018321 A1 AR 018321A1 AR P990100963 A ARP990100963 A AR P990100963A AR P990100963 A ARP990100963 A AR P990100963A AR 018321 A1 AR018321 A1 AR 018321A1
Authority
AR
Argentina
Prior art keywords
oxibutinine
dosage form
prolonged liberation
liberation
prolonged
Prior art date
Application number
ARP990100963A
Other languages
English (en)
Spanish (es)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR018321A1 publication Critical patent/AR018321A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP990100963A 1998-03-26 1999-03-05 Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. AR018321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7942998P 1998-03-26 1998-03-26

Publications (1)

Publication Number Publication Date
AR018321A1 true AR018321A1 (es) 2001-11-14

Family

ID=22150487

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100963A AR018321A1 (es) 1998-03-26 1999-03-05 Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.

Country Status (5)

Country Link
US (1) US20010009995A1 (enExample)
JP (1) JP2002507566A (enExample)
AR (1) AR018321A1 (enExample)
AU (1) AU3103799A (enExample)
WO (1) WO1999048494A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6403600A (en) * 1999-06-10 2001-01-02 Sepracor, Inc. Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN1438861A (zh) 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US5480651A (en) * 1992-03-16 1996-01-02 Regents Of The University Of California Composition and method for treating nicotine craving in smoking cessation
JP2665858B2 (ja) * 1992-05-30 1997-10-22 日本ヘキスト・マリオン・ルセル株式会社 持効性塩酸オキシブチニン製剤
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
ATE214229T1 (de) * 1996-04-11 2002-03-15 Basf Ag Fungizide mischungen
WO1998043555A1 (en) * 1997-04-03 1998-10-08 Point Biomedical Corporation Intravesical drug delivery system
CN1438861A (zh) * 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin

Also Published As

Publication number Publication date
JP2002507566A (ja) 2002-03-12
AU3103799A (en) 1999-10-18
US20010009995A1 (en) 2001-07-26
WO1999048494A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
MX9302867A (es) Composiciones refrescantes.
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES551119A0 (es) Procedimiento para preparar un agente analgesicamente activo a base de 2-amino-3-carboetoxiamino-6-(4-fluorobencilamino)-piridina y por lo menos un agente antiflogistico no esteroidal
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
DE19681389T1 (de) Dosierungsform, umfassend Oxybutynin
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
EE9700195A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR002157A1 (es) Uso de una dosis inmunizante eficaz de esporozoitos o merozoitos de eimeria vivos, o una mezcla de los mismos
BR9806213A (pt) Forma de dosagem transdérmica.
NO963749L (no) Transdermalt system i form av et plaster med et tamoxifen-derivat
CY1105465T1 (el) Μορφη δοσολογιας πepιλαμβανουσα υγρο σκευασμα
ES2163896T3 (es) Composiciones para aumentar la concentracion y/o motilidad de los espermatozoos en humanos.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
UY25357A1 (es) Nuevos pentasacáridos, procedimiento para su preparación y composiciones farmacéuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure